What is Bioptix?
Bioptix operates at the intersection of advanced biological research and clinical diagnostics, providing a comprehensive suite of reagents, assay kits, and specialized cell lines. The company serves a diverse clientele spanning academic institutions, pharmaceutical enterprises, and clinical laboratories. By focusing on high-quality tools for oncology, immunology, and molecular biology, Bioptix has established itself as a critical enabler of scientific discovery and improved patient outcomes.
The firm's market position is defined by its commitment to technical excellence and its ability to support complex research workflows. Through its specialized product offerings, Bioptix addresses the evolving needs of the life sciences sector, ensuring that researchers and healthcare professionals have access to the precise instrumentation and chemical reagents required for high-stakes diagnostic testing and experimental validation.
How much funding has Bioptix raised?
Bioptix has raised a total of $22.7M across 8 funding rounds:
Unspecified
$3.4M
Unspecified
$1.2M
Unspecified
$4.5M
Unspecified
$6.2M
Private Equity
$2.1M
Private Equity
$1.4M
Private Equity
$1.5M
Private Equity
$2.5M
Unspecified (2009): $3.4M with participation from Boulder Ventures
Unspecified (2010): $1.2M, investors not publicly disclosed
Unspecified (2011): $4.5M supported by Boulder Ventures
Unspecified (2013): $6.2M, investors not publicly disclosed
Private Equity (2014): $2.1M, investors not publicly disclosed
Private Equity (2014): $1.4M with participation from Boulder Ventures, Rusnano, and Remeditex
Private Equity (2015): $1.5M, investors not publicly disclosed
Private Equity (2015): $2.5M, investors not publicly disclosed
Key Investors in Bioptix
Boulder Ventures
Boulder Ventures Ltd. is a venture capital firm that specializes in investing in IT and biotech companies located in Colorado and the Mid-Atlantic region. The firm has a portfolio that includes 61 companies, with 28 successful exits and 10 initial public offerings (IPOs).
Rusnano
Группа РОСНАНО specializes in the development and optimization of advanced technologies in fields such as microelectronics, biotechnology, and material morphology. The company aims to support various industries by providing innovative solutions and services.
Remeditex
Remeditex seeks to develop opportunities in need of commercial validation, guidance, and capital. Its mission is to develop early stage biomedical science and make Texas and Colorado a preferred location for biotechnology companies.
What's next for Bioptix?
With the successful closure of this latest financing round, Bioptix is poised to enter a new phase of operational scaling and product diversification. The strategic deployment of these funds will likely focus on enhancing the company's R&D capabilities, potentially accelerating the commercialization of new diagnostic assays and expanding its reach into emerging markets. As the firm continues to navigate the complexities of the biotech industry, the focus remains on maintaining its competitive edge through innovation and strategic partnerships.
Looking ahead, the company is expected to leverage its strengthened balance sheet to pursue aggressive growth objectives. By deepening its engagement with the pharmaceutical and clinical sectors, Bioptix aims to solidify its role as a foundational provider of essential biological research tools, ultimately driving long-term value for its stakeholders and contributing to the advancement of global healthcare standards.
